HTG Receives Phase II SBIR Award to Continue Development of Sequencing Products | GenomeWeb

NEW YORK (GenomeWeb News) – The National Human Genome Research Institute has awarded HTG Molecular Diagnostics a $1.01 million award to continue development of targeted sequencing products, the Tucson, Ariz.-based company said today.

The one-year Phase II Small Business Innovation Research grant allows HTG to continue work that was carried out under a $599,000 Phase I SBIR grant to the company for the Nuclease Robe Mediated Sequencing Project (HTG EdgeSeq), which seeks to develop targeted sequencing products using HTG's core RNA analysis technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.